Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

References

• Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2019;25(2):e46–e54.
   Google Scholar
• Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168.
   PubMed Web of Science ®Google Scholar
• Ferrara JLM, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561.
   PubMed Web of Science ®Google Scholar
• Munir SZ, Aylward J. A review of ocular graft-versus-host disease. Optom Vis Sci. 2017;94(5):545–555.
   PubMed Web of Science ®Google Scholar
• Riemens A, Te Boome L, Imhof S, et al. Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol. 2010;21(6):485–494.
   PubMed Web of Science ®Google Scholar
• Khanal S, Tomlinson A. Tear physiology in dry eye associated with chronic GVHD. Bone Marrow Transplant. 2012;47(1):115.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22(Supplement 1):S19–S27.
   PubMedGoogle Scholar
• Zallio F, Mazzucco L, Monaco F, et al. A single-center pilot prospective study of topical application of platelet-derived eye drops for patients with ocular chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1664–1670.
   PubMed Web of Science ®Google Scholar
• Wang JCC, Teichman JC, Mustafa M, et al. Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD. Br J Ophthalmol. 2015;99(11):1514–1518.
   PubMed Web of Science ®Google Scholar
• Tatematsu Y, Ogawa Y, Abe T, et al. Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score. Sci Rep. 2015;4(1):6680.
   Google Scholar
• Curtis LM, Datiles MB, Steinberg SM, et al. Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica. 2015;100(9):1228–1236.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Shimmura S, Dogru M, et al. Immune processes and pathogenic fibrosis in ocular chronic graft-versus-host disease and clinical manifestations after allogeneic hematopoietic stem cell transplantation. Cornea. 2010;29:S68–S77.
   PubMedGoogle Scholar
• Ogawa Y, Kim SK, Dana R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (part I). Sci Rep. 2013;3(1):3419.
   PubMedGoogle Scholar
• Zhong M, Gadek TR, Bui M, et al. Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye. ACS Med Chem Lett. 2012;3(3):203–206.
   PubMed Web of Science ®Google Scholar
• Sato T, Habtezion A, Beilhack A, et al. Short-term homing assay reveals a critical role for lymphocyte function-associated antigen-1 in the hepatic recruitment of lymphocytes in graft-versus-host disease. J Hepatol. 2006;44(6):1132–1140.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li D, Jones D, et al. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(12):1513–1522.
   PubMed Web of Science ®Google Scholar
• Ohno J, Iwahashi T, Ehara M, et al. Induction of epithelial migration of lymphocytes by intercellular adhesion molecule-1 in a rat model of oral mucosal graft-versus-host disease. Histol Histopathol. 2011;26(6):725–733.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase iii, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18:1517–1524.
   PubMed Web of Science ®Google Scholar
• Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083–1094.
   PubMed Web of Science ®Google Scholar
• Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. OPTH. 2018;12:125–139.
   Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–215.
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050–1060 e1.
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015;21(6):984–999.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:e46–e54.
   PubMedGoogle Scholar
• Wang Y, Ogawa Y, Dogru M, et al. Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. Bone Marrow Transplant. 2010;45(6):1077.
   PubMed Web of Science ®Google Scholar
• Westeneng AC, Hettinga Y, Lokhorst H, et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea. 2010;29(7):758–763.
   PubMed Web of Science ®Google Scholar
• Ali TK, Gibbons A, Cartes C, et al. Use of autologous serum tears for the treatment of ocular surface disease from patients with systemic autoimmune diseases. Am J Ophthalmol. 2018;189:65–70.
   PubMed Web of Science ®Google Scholar
• Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93(8):e605–e614.
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Di Zazzo A, Satitpitakul V, et al. A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of janus kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease. Cornea. 2017;36(7):799–804.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012;119(3):487–493.
   PubMed Web of Science ®Google Scholar